Financings in Brief: Abaxis
This article was originally published in The Gray Sheet
Executive Summary
Abaxis: Nets $6.1 mil. from a private offering of 980,000 new common shares to a foreign investor. The blood analysis systems manufacturer says the proceeds will be used to commercialize its Piccolo portable blood analyzer and its VetScan veterinary products. Sunnyvale, California-based Abaxis recently entered a non-exclusive agreement with Baxter for distribution of the Piccolo, formerly known as the Epoc 2000, in the U.S. The system is scheduled for rollout in September, Abaxis says. The offering brings Abaxis' outstanding shares to 9.7 mil...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.